Literature DB >> 10743688

Ogilvie's syndrome associated with acute cytomegaloviral infection after liver transplantation.

A M Shapiro1, V G Bain, J K Preiksaitis, M M Ma, S Issa, N M Kneteman.   

Abstract

Ogilvie's syndrome, or acute colonic pseudo-obstruction, is a rare complication following liver transplantation. We describe two cases in which the onset of Ogilvie's syndrome is strongly temporally associated with acute cytomegaloviral (CMV) infection in immunosuppressed liver transplant recipients. The pseudo-obstruction resolved rapidly in both cases following treatment with intravenous ganciclovir. Acute CMV infection therefore appeared to be causally linked to pathogenesis of Ogilvie's syndrome in these two cases. This association has not been described previously to our knowledge, and should be considered in any transplant patient presenting with Ogilvie's syndrome.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10743688     DOI: 10.1007/s001470050006

Source DB:  PubMed          Journal:  Transpl Int        ISSN: 0934-0874            Impact factor:   3.782


  3 in total

1.  Comparison of LightCycler-based PCR, COBAS amplicor CMV monitor, and pp65 antigenemia assays for quantitative measurement of cytomegalovirus viral load in peripheral blood specimens from patients after solid organ transplantation.

Authors:  Xiaoli L Pang; Linda Chui; Jayne Fenton; Barbara LeBlanc; Jutta K Preiksaitis
Journal:  J Clin Microbiol       Date:  2003-07       Impact factor: 5.948

2.  Cytomegalovirus-induced small-bowel hemorrhage in a patient with nonsystemic vasculitic neuropathy.

Authors:  Toshiro Sugimoto; Mariko Soumura; Masayasu Kawasaki; Hiromichi Kawai; Takashi Uzu; Yoshihiko Nishio; Tohru Tani; Atsunori Kashiwagi
Journal:  Clin Rheumatol       Date:  2006-01-11       Impact factor: 2.980

3.  Acute colonic pseudo-obstruction: A systematic review of aetiology and mechanisms.

Authors:  Cameron I Wells; Gregory O'Grady; Ian P Bissett
Journal:  World J Gastroenterol       Date:  2017-08-14       Impact factor: 5.742

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.